MAM
Labourhome empowers 700 construction worker families via Ola Electric factory project
Mumbai: Labourhome, an end-to-end workforce management enterprise, announces its pivotal role in constructing Ola Electric’s two-wheeler manufacturing facility in Hosur. This landmark project not only advances India’s electric vehicle sector but also underscores Labourhome’s commitment to enhancing the lives of construction workers and their families.
Labourhome was instrumental in sourcing and deploying over 700 skilled workers, generating more than 240,000 man-days of employment for the EPC Construction Agency appointed by OLA Electric for the Project. This achievement reflects the company’s dedication to providing stable and meaningful employment opportunities in large-scale infrastructure projects.
The company’s commitment extended beyond employment to include comprehensive support for workers’ welfare. Labourhome ensured stable employment, provided secure accommodations, and offered healthcare support, directly benefiting 700 construction worker families.
EPC Construction Agency project director Jaishankar commented, “The Ola Electric project is one of the largest EV two-wheeler factories in Asia, and its successful completion in record time is a testament to the dedication and efficiency of our partners. Labourhome’s role in managing the workforce was crucial to our success. Their commitment to providing skilled labor and ensuring worker welfare significantly contributed to this landmark project’s timely and successful completion.”
“We are honored to contribute to this transformative project and make a positive impact on the lives of 700 construction worker families,” stated Labourhome founder R.Vinoth Kumar.” Our collaboration with OLA Electric Project highlights our capacity to manage large-scale workforce deployments and our unwavering commitment to improving workers’ lives.”
Labourhome’s involvement in the Ola Electric two-wheeler factory project underscores its role as a key player in supporting major infrastructure projects while enhancing the livelihoods of workers and their families.
One notable impact of Labourhome’s efforts is the story of Ravi, a construction worker who experienced significant improvements in financial stability because of which he was able to provide his children education for the first time.
Labourhome’s effective workforce management was crucial in maintaining the project’s timeline and efficiency. By ensuring a steady flow of skilled labor and focusing on worker welfare, Labourhome helped minimize delays and ensured the smooth execution of key project phases.Hereby, Labourhome has not only significantly improved the livelihood of these workers and their families but also managed to complete the OLA Electric EV Two Wheeler factory project in a timely manner.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
